IARC List of Carcinogens: Classification Guide

The IARC list of carcinogens is an authoritative reference catalog maintained by the International Agency for Research on Cancer (IARC) that classifies environmental, chemical, physical, and biological agents by the strength of scientific evidence regarding their potential to cause cancer in humans. Operating under the IARC Monographs programme, this catalog identifies carcinogenic hazards rather than calculating individual exposure risk or dose-response probabilities. In oncology research and chemical safety evaluations, these classifications provide global public health bodies, toxicologists, and clinical researchers with an evidence-based foundation for cancer hazard identification.

Understanding cancer etiology and comparative risk mechanisms connects directly to broader foundational concepts in oncology, where toxicologists and epidemiologists translate observational findings into protective public health frameworks.

What it is

The IARC carcinogen list represents the cumulative output of the IARC Monographs on the Identification of Carcinogenic Hazards to Humans. Established in 1971 by resolution of the IARC Governing Council, the series evaluates peer-reviewed scientific studies to determine whether specific exposures present a carcinogenic hazard to humans.

A central scientific principle of the IARC system is the distinction between hazard identification and quantitative risk assessment:

Hazard identification: Determines whether an agent is capable of causing cancer under any exposure condition. The IARC Monographs evaluate hazard identification exclusively.
Risk assessment: Quantifies the actual probability of cancer occurring in human populations at specific exposure levels, daily doses, or ambient concentrations. Risk assessment falls under national regulatory bodies (such as the US EPA, OSHA, and EFSA), not IARC working groups.

Following methodology updates in the amended January 2019 Preamble to the IARC Monographs, evaluations integrate three independent evidence streams: human epidemiological studies, experimental animal bioassays, and mechanistic evaluations.

Who runs it and what it covers

The IARC Monographs programme is operated by the International Agency for Research on Cancer, a specialized cancer agency of the World Health Organization (WHO) located in Lyon, France. The programme convenes independent interdisciplinary Working Groups of international scientists free of commercial conflicts of interest.

Through Volume 142 (with database records current through October 2026), the IARC has evaluated 1,060 agents across four active groups:

IARC Group 1 carcinogens (Carcinogenic to humans — 135 agents): Assigned when there is sufficient evidence of carcinogenicity in humans from epidemiological studies where bias, confounding, and chance can be ruled out. Group 1 may also apply when there is strong mechanistic evidence in exposed humans exhibiting key characteristics of carcinogens alongside sufficient evidence in experimental animals. Examples include ionizing radiation, benzene, and formaldehyde.
IARC Group 2A (Probably carcinogenic to humans — 98 agents): Assigned when at least two evidence evaluations are established, with at least one involving exposed humans or human cells and tissues (such as limited human evidence paired with sufficient animal evidence, or strong mechanistic data). Examples include night shift work and glyphosate.
IARC Group 2B (Possibly carcinogenic to humans — 329 agents): Assigned when only one primary line of evidence is established, such as limited human evidence, sufficient animal evidence, or strong mechanistic evidence in experimental systems.
IARC Group 3 (Not classifiable as to its carcinogenicity to humans — 498 agents): Assigned when available scientific evidence is inadequate or inconclusive in humans and animal models. Group 3 indicates an absence of definitive research rather than proof of safety or non-carcinogenicity.

Under the 2019 Preamble revision, the former Group 4 category (“Probably not carcinogenic to humans”) was removed because proving a complete negative across all potential human cancer sites and life stages is scientifically unprovable; substances previously in Group 4 were reassigned to Group 3.

How to search or use it

Researchers and compliance professionals consult official IARC ratings through the online IARC Monographs Database Online (IARC-MonDO) and published volume repositories using these steps:

Access the online database: Navigate to the IARC Monographs classifications portal at monographs.iarc.who.int and select “Classifications”, or open the IARC-MonDO interface directly.
Input search query: Enter the chemical name, trade synonym, biological agent, or Chemical Abstracts Service (CAS) number into the search field.
Filter by classification tier: Use filter controls to isolate tiers (Group 1, Group 2A, Group 2B, or Group 3), agent classes, or target cancer sites.
Inspect evaluation summary: Check the returned record to confirm the overall classification, Monograph volume number, publication year, and documented human cancer sites.
Examine evidence streams: Review the three underlying streams: human epidemiology, animal bioassays, and mechanistic markers.
Download documentation: Export tabular data in spreadsheet format, or open the Monograph PDF to review the full consensus rationale.

In research facilities handling chemical compounds, hazard ratings from Group 1 and Group 2A frequently trigger institutional controls under regulations such as the Hazard Communication Standard in laboratories and safety protocols for particularly hazardous substances.

Strengths and limits

The IARC Monographs provide an internationally recognized benchmark for carcinogenic hazard identification, structured around standardized evidentiary criteria.

Strengths

Rigorous conflict-of-interest management: Working Group members are chosen solely for scientific expertise and must disclose potential conflicts; representatives of commercial entities may only participate as non-voting observers.
Standardized Preamble criteria: Systematic evidentiary rules ensure uniform review standards across epidemiology, animal pathology, and molecular toxicology.
Mechanistic integration: Evaluating substances against the “10 Key Characteristics of Carcinogens” allows working groups to incorporate genomic, metabolomic, and in vitro evidence alongside classical bioassays.

Limits

No exposure potency metrics: Classifications indicate whether an agent can cause cancer, not the required dose. Two compounds in Group 1 may differ drastically in the exposure intensity or duration required to induce tumors.
Update latency: Monograph volumes require multi-year planning and working group convening; literature published between evaluation cycles is not reflected immediately in classifications.
Public conflation of hazard and risk: External audiences sometimes mistake hazard identification for personal risk, resulting in misinterpretations of Group 2A and Group 2B designations.

Alternatives

Several national and international health agencies maintain chemical carcinogenicity databases. While IARC focuses on hazard identification, other agencies incorporate quantitative risk assessment or statutory labeling thresholds:

Organization / Platform	Primary Mandate	Classification Framework	Key Evidentiary Output
IARC Monographs (WHO)	Global carcinogenic hazard identification	Group 1, Group 2A, Group 2B, Group 3 (4 active groups)	Consensus Monograph volumes; qualitative hazard tiers; mechanistic profiles
NTP Report on Carcinogens (US HHS / NIEHS)	Congressionally mandated US public health compendium	Known to be a human carcinogen; Reasonably anticipated to be a human carcinogen (2 groups)	Biennial report profiles; exposure assessments; US population exposure summaries
EPA IRIS (US Environmental Protection Agency)	Quantitative human health toxicological assessment	Five narrative cancer descriptors (e.g., Carcinogenic to humans, Likely, Suggestive)	Cancer slope factors (CSF); inhalation unit risks (IUR); reference doses (RfD)
EU CLP / ECHA (European Chemicals Agency)	Legally binding chemical classification and labeling	Category 1A (known), Category 1B (presumed), Category 2 (suspected)	Hazard statements (H350, H351); safety data sheet (SDS) mandatory thresholds

Investigative programs examining carcinogens frequently operate alongside national funding mechanisms such as NCI funding and initiatives outlined in our cancer research funding overview.

FAQ

What is the difference between IARC Group 2A and Group 2B?

Group 2A (“probably carcinogenic to humans”) requires at least two converging evidence streams—such as limited evidence of cancer in humans and sufficient evidence in experimental animals, with at least one stream showing biological activity in human cells or tissues. Group 2B (“possibly carcinogenic to humans”) requires only one primary stream, such as sufficient evidence in animal models alone without corroborating human data.

Does an IARC Group 1 classification mean an exposure is high risk?

No. An IARC Group 1 classification indicates conclusive scientific proof that an agent is capable of causing cancer in humans, but it does not measure personal risk, biological potency, or necessary exposure duration. Both sunlight and tobacco smoke are Group 1 carcinogens, yet individual risk depends entirely on exposure magnitude, cumulative duration, and individual susceptibility.

Why is there no Group 4 in the current IARC classification?

In the amended 2019 Preamble, Group 4 (“probably not carcinogenic to humans”) was removed because proving a definitive negative across all cancer sites, exposure conditions, and life stages is scientifically unprovable. Substances that previously held Group 4 status were moved to Group 3, where specific evaluation notes can indicate that an agent is well-studied without evidence of carcinogenic activity.

How does mechanistic evidence affect an IARC evaluation?

Working Groups evaluate mechanistic literature against the “10 Key Characteristics of Carcinogens” (including genotoxicity, epigenetic alteration, oxidative stress, and chronic inflammation). Strong mechanistic findings from exposed humans or human tissues can elevate an agent with limited epidemiological data into Group 2A or Group 1.

Sources

International Agency for Research on Cancer (IARC / WHO). Agents Classified by the IARC Monographs, Volumes 1–142. Published online; updated October 30, 2026. Available at: https://monographs.iarc.who.int/agents-classified-by-the-iarc/.
International Agency for Research on Cancer (IARC / WHO). Preamble to the IARC Monographs on the Identification of Carcinogenic Hazards to Humans (Amended January 2019). Available at: https://monographs.iarc.who.int/wp-content/uploads/2019/07/Preamble-2019.pdf.
National Toxicology Program (US Department of Health and Human Services / National Institute of Environmental Health Sciences). 15th Report on Carcinogens. Available at: https://ntp.niehs.nih.gov/whatwestudy/assessments/cancer/roc.
US Environmental Protection Agency (EPA). Integrated Risk Information System (IRIS): Carcinogenicity Assessment Guidelines. Available at: https://www.epa.gov/iris.